Language
BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs
BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns
Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis
Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance
Sangamo Therapeutics Aligns with FDA on Accelerated Approval Pathway for ST-920 Gene Therapy in Fabry Disease
Sangamo Therapeutics, FDA, Accelerated Approval Pathway, ST-920, Fabry Disease, Gene Therapy, BLA Submission
BIOSECURE Act: Navigating Industry Implications and Future Directions
BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience
Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera
Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates
BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties
BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare
US Speaker Promises Vote on BIOSECURE Act to Halt Federal Contracts with Chinese Biotech Companies
BIOSECURE Act, House Speaker Mike Johnson, Chinese biotech companies, federal contracts, healthcare data, national security
SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies
SciRhom, autoimmune diseases, iRhom2, therapeutic strategy, Series A funding, biotech, pharmaceuticals
Grifols Founding Family and Brookfield Plan to Take Drugmaker Private
Grifols, Brookfield, Private Equity, Takeover Bid, Spanish Drugmaker, Nasdaq, Spanish Stock Exchange